heat shock protein family A (Hsp70) member 2Genealiases: HSP70-2 · HSP70-3
Q-omics provides the consensus-scored HSPA2 profile across patient tissues and cancer cell-line models. HSPA2 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, HSPA2 is differentially expressed in 16, with the highest sampling consensus in KIRC. Additionally, HSPA2 protein abundance shows 23,343 significant protein co-abundance associations, with the highest sampling consensus in PDAC. Together, these results highlight BRCA, KIRC, and PDAC as cancer lineages where HSPA2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for HSPA2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes HSPA2 survival associations across molecular data types. HSPA2 RNA expression shows survival associations in the most cancer types (20), followed by mutation status (11) and mass-spec protein abundance (9). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible HSPA2 RNA expression–survival associations across cancer types. High HSPA2 expression shows unfavorable associations in BLCA, SKCM and LUAD, but favorable associations in BRCA, ACC and SCLC. The BRCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for HSPA2 RNA expression.
This table summarizes HSPA2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 16, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for HSPA2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. HSPA2 shows lower tumor expression in KIRC, BLCA, THCA, KICH, COAD and KIRP. The KIRC box plot shows higher HSPA2 RNA expression in normal versus tumor tissue (log2 FC = −3.714, t-test p < 0.001).
This table shows molecular features associated with HSPA2 in patient tissues and cancer cell lines. In patient samples, HSPA2 shows the broadest associations at the RNA and protein expression levels, with PDAC recurring as the lineage with the largest associated feature set. In cancer cell lines, HSPA2 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUSC, while CRISPR and shRNA rows add functional-dependency signals in BREAST and UPPER_AERODIGESTIVE_TRACT.
